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A Survey of the Current Practice of Intramuscular Botulinum Toxin 
Injections for Hemiplegic Shoulder Pain in the UK 
 
Abstract 
 
Purpose: To describe the current UK practice for the use of intramuscular Botulinum Toxin type A 
injections to treat hemiplegic shoulder pain. 
Method: A UK-based cross-sectional study using an online survey.  Participants (n=68) were medical 
and non-medical practitioners recruited via the membership of the British Society for Rehabilitation 
Medicine and the British Neurotoxin Network.  Data was analysed using descriptive statistics and 
content analysis. 
Results: The majority of respondents would consider Botulinum Toxin type A for hemiplegic shoulder 
pain (86.8%), though most of these respondents inject for this goal infrequently (83.1%).  Pectoralis 
major was most commonly selected to achieve this goal.  Barriers to this intervention included 
difficulties determining the cause of pain (29.4%), difficulty isolating muscles (27.9%), and a lack of 
evidence (25%).  The doses reported regularly deviated from guidelines and a substantial range in the 
volumes suggested was observed.  Clinicians were mostly reliant on unstandardised measures to assess 
outcomes. 
Conclusions: Current UK practice of Botulinum Toxin type A injections for hemiplegic shoulder pain 
associated with spasticity is highly variable.  There are large gaps between current practice and available 
evidence with regards to muscle selection and doses used.  A number of areas for further investigation 
have been identified to progress current understanding of this intervention. 
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Background 
 
Hemiplegic shoulder pain (HSP) is a common complication following stroke ranging in 
incidence between 23% [1] to 40% [2] at six months, with a peak onset of four months [3].  It 
is associated with an increased length of stay during inpatient rehabilitation and is an important 
predictor of poor functional outcome in the upper limb [4,5].  It has been shown to be 
significantly associated with reduced quality of life at 12 months post-stroke [6], as well as 
impacting on a patient’s mood, activities of daily living and participation in leisure activities 
to a great extent [7]. 
HSP is thought to be multifactorial in causation, encompassing both neurological (of 
central or peripheral nature) and mechanical (traumatic and insidious) factors [8].  
Consequently, the range of available treatment modalities is vast with one exploratory study 
identifying 175 different therapeutic interventions under 13 themes [9].  Roosink et al [10] 
recommend a multifactorial approach to treatment but to do this there needs to be a clear 
diagnostic process to identify the different aspects of HSP at play.  Unfortunately, it remains 
unclear in the literature what the optimal treatment modalities for the various subtypes of HSP 
are and, in practice, linking the causation with the most effective intervention remains 
problematic. 
Studies have found a high correlation between HSP and decreased range of passive 
shoulder movement [11,12], but it is unclear if this is a causative relationship and in practice it 
is difficult to distinguish the degree to which different factors (such as contracture, spasticity, 
or adhesive capsulitis) contribute to the restriction and pain [13].  A number of randomised 
controlled studies have hypothesised that HSP associated with range-limiting spasticity around 
the shoulder girdle may improve with intramuscular Botulinum Toxin type A (BoNT-A) 
injections [14-19].  However, these studies found conflicting results likely secondary to the 
variability in doses, dilutions and products used as well as the range of muscles selected to 
treat.  They also lacked attention to activity-based or goal-orientated outcome measures.  
Because of this variability in methodology, definitive recommendations to achieve the optimal 
effectiveness of this treatment modality are not currently possible.  
A Cochrane review [20] and a meta-analysis [21] reviewed BoNT-A injections for HSP 
and both found the evidence favoured the intervention.  However, the few studies they 
reviewed were limited by low powered randomised controlled trials and a high potential for 
bias.  The recent Royal College of Physicians’ guidelines for stroke [22] also comment that 
whilst BoNT-A injections showed positive benefits in reducing pain and improving function 
and range of movement, there remains a need for larger, high-quality randomised controlled 
trials before the intervention can be confidently recommended in routine clinical practice. 
In the future, these larger-scale studies will need to explore the factors that contribute 
to optimising effective patient selection, muscle selection and dosage.  However, prior to this 
it would be useful to understand the current ‘state of play’ to see if there is a consensus in the 
application of this intervention in practice and to identify any gaps between the available 
evidence and contemporary practice.  With this in mind, an online survey was undertaken with 
the aim of ascertaining the current practice for the use of intramuscular BoNT-A injections to 
treat HSP in the UK and to compare this to existing guidelines. 
 
 
 
  
Method 
 
Study design 
A UK-based cross-sectional study design was used with data collected via an online survey.  
Ethical approval was granted by the University of Central Lancashire Research Ethics 
Committee (reference number STEMH 595). 
 
Survey design 
A review was carried out to identify any valid and reliable tools within the literature.  As none 
were identified, an original survey was designed using the online survey tool, 
SurveyMonkey®.  The survey consisted of three sections – (i) Demographics, (ii) Assessment 
and Treatment, and (iii) Factors Affecting Clinical Decision Making.  The questionnaire 
utilised a mix of multiple-choice, Likert scales and open-ended questions.  A question skip 
logic was applied whereby if participants would not consider using BoNT-A for HSP 
associated with spasticity then they skipped questions related to the methods used for such 
injections. 
During the development and refining stage, the survey was initially trialled on a group 
of eight professionals including two doctors and six physiotherapists.  These were a mix of 
professionals with a knowledge of the topic matter (n=3), a knowledge of research methods 
(n=2), and “lay-persons” with no specific expertise in either (n=3).   A second round of testing 
(n=4) was undertaken to assess usability and for further revisions to be made to the 
questionnaire.  Prior to distribution the survey was peer reviewed by the Research and Clinical 
Standards Committee at the British Society for Rehabilitation Medicine, following which the 
structure and content of the survey was finalised (Supplemental online material).  
 
Participants 
The sample population for this study was medical and non-medical practitioners in the UK who 
inject BoNT-A for spasticity management as part of their current practice.  The British Society 
for Rehabilitation Medicine and the British Neurotoxin Network distributed the link to the 
online survey to their members via email.  The email contained the participant information 
sheet as an attachment and recipients were asked to forward the link on to other practitioners 
as appropriate, thus sourcing additional participants via snowball sampling.  A second email 
was distributed two weeks later to act as a reminder. 
Participants were advised that completion of the survey would be taken as their 
informed consent.  The use of the online survey tool ensured participants anonymity remained 
intact.  No incentives were offered for involvement in the study. 
 
Data analysis 
Data was collected and securely stored on the SurveyMonkey® website.  Data was then 
downloaded into an Excel format and imported into SPSS for analysis.  Descriptive statistics 
were used to describe, synthesise, and summarise the data.  Content analysis was used to collate 
and report the responses from open-ended responses. 
During analysis, Likert scales were recoded to group together positive, neutral and 
negative responses.  Doses were also recoded as under, over or within the recommended dose 
range when compared to the RCP National Guidelines: Spasticity in Adults [23].  As these 
guidelines do not provide recommended doses for Xeomin®, a conversion ratio of 1:1 
(Botox®: Xeomin®) was used as described by Dressler et al [24].  Due to low frequencies of 
most muscles reported, only the five most commonly suggested muscles had sufficient data to 
analyse the doses and volumes used. 
  
Results 
 
Participant demographics 
The survey link was distributed to 217 members of the British Neurotoxin Network and 305 
members of the British Society for Rehabilitation Medicine, giving a total of 522 recipients.  
Although it was not possible to identify the exact number of appropriate practitioners who 
received the link, a total of 93 participants responded giving an approximate initial response 
rate of 17.8%. Of these, 25 respondents submitted incomplete questionnaires and were 
therefore excluded from the study.  Consequently, 68 completed questionnaires were included 
in the final analysis giving an actual response rate of 13.0%.  The demographic characteristics 
of these participants can be seen in Table 1.  
All areas of the UK were represented within the data (Figure 1).  Practitioners had been 
qualified in the range between five to 46 years (mean=22.57 years, SD=9.23 years).  Their 
highest academic qualifications were grouped into graduate (35.3%), post-graduate (27.9%), 
and doctoral (26.5%) levels with some respondents citing higher medical qualifications (FRCP 
5.9%, MRCP 2.9%, FRCSI 1.5%).  Over half (54.4%) had been injecting BoNT-A for over 10 
years and approximately a third (33.8%) performed over 20 injections per month (Table 1).  
Respondents reported injecting BoNT-A in a range of settings including inpatient acute wards 
(55.9%), inpatient rehabilitation wards (77.9%), outpatient clinics (88.2%), and on domiciliary 
visits (42.6%). 
 
Clinician’s use and experience 
The majority of respondents reported that they would consider injecting intramuscular BoNT-
A for HSP associated with spasticity (86.8%).  Due to limited numbers across demographic 
factors it was not possible to calculate any statistical differences between groups.  Just over 
half (54.4%) agreed or strongly agreed that BoNT-A is an effective treatment for HSP.  
However, it is often not their first-line treatment choice with only 8.8% agreeing or strongly 
agreeing to this effect.  
Despite the high number of respondents who would inject, only 45.6% reported they 
had no barriers to injecting BoNT-A for HSP.  The main barriers that respondents reported 
were difficulties determining the cause of pain (29.4%), difficulty isolating the muscles to 
inject (27.9%), and a lack of evidence (25%) (Table 2). 
Of the clinicians who would consider injections (n=59) the majority (83.1%) had only 
performed three or less injections for the goal of reducing HSP in the last three months.  When 
deciding on the timings of injections post-stroke, the majority of clinicians would consider 
injecting at the stages ‘1-3 months’ and ‘3-6 months’ (83.1%).  This is in contrast to the ‘0-13 
days’ stage where only 11.9% of clinicians would consider injecting BoNT-A for HSP.  
With regards to signs and symptoms that would lead respondents to believe that HSP 
was due to spasticity over other causes, the most common reported were ‘Limitation of 
shoulder abduction’ (71.2%), ‘Limitation of shoulder external rotation’ (69.5%), ‘Flexor 
patterning in the upper limb’ (61.0%), and ‘Pain on passive movement’ (54.2%) (Table 3). 
Content analysis found few adverse effects with four respondents reporting the usual 
side effects of localised pain and bruising at the injection site, four respondents reporting 
increased/worsening subluxation, and one respondent reporting that the shoulder was more 
painful following injections if not supported with a brace.  There was only one report of a 
serious adverse event in which a patient suffered dysphagia following injections that included 
muscles around the shoulder.  However, it was unclear which muscles were injected and 
whether this was done for the goal of reducing HSP.  In support of the low number of reported 
problems, only 4.4% agreed or strongly agreed that BoNT-A injections for HSP cause adverse 
effects. 
 Current practice 
The primary muscle that clinicians chose to inject most commonly was pectoralis major, being 
the first choice of 67.8% of the questioned cohort (n=59).  Other muscles considered as first 
choice were subscapularis (10.2%), supraspinatus (5.1%), biceps brachii (1.7%), teres major 
(1.7%), and infraspinatus (1.7%).  When collating all responses, including second and third 
choices, there was a wide range of muscles suggested and the frequencies for each can be seen 
in Table 4. 
There was a large degree of variation observed with regards to the doses and volumes 
of injectate used.  The most common muscle identified (pectoralis major) was reported to be 
injected below the recommended dose by just under half of respondents, whilst for other 
muscles (subscapularis and teres major) there was a trend towards higher than recommended 
doses.  The volumes of injectate used also showed a substantial degree of variability for all 
muscles analysed.  This was most strikingly apparent for pectoralis major, subscapularis and 
latissimus dorsi whereby the maximum volume recommended by respondents was 10 to 16-
times greater than the minimum volume.  Data for the doses and volumes of the five most 
common muscles is summarised in Table 5. 
Content analysis of how clinicians assess the effectiveness of injections for HSP found 
that only 33.9% of respondents referred to a standardised outcome measure.  The most common 
outcome measures reported were visual analogue scale (22.0%, n=13), and goal attainment 
scaling (11.9%, n=7).  However, more often clinicians referred to the use of unstandardised 
subjective and objective assessment with 27.1% (n=16) of respondents citing patient, carer or 
therapist reports, and 16.9% (n=10) citing clinician subjective review. 
 
  
Discussion 
 
The main finding of this study was the wide variation in practice reported for the goal of 
treating spasticity associated HSP with BoNT-A.  This is in support of the Upper Limb 
International Spasticity (ULIS)-II study [25] who also described a wide variation in practice in 
relation to treatment goals for the upper limb.  However, whereas ULIS-II reported BoNT-A 
treatment for upper limb spasticity in general, this study focussed specifically on a single goal 
of intervention thereby making the observation even more unexpected. 
Whilst it is acknowledged that the complexities of spasticity as well as HSP demand an 
individualised treatment intervention [26], it was not expected that practice would be so widely 
varied with regards to muscle selection, dose, and volume as well as the outcome measures 
used.  Baguley et al [27] explored the decision-making practices with regards to BoNT-A use 
for adult upper limb spasticity and found that the muscle selection and doses used were not 
significantly associated with the goals of treatment or the severity of spasticity.  They 
concluded that injector beliefs more so than patient characteristics were the main force guiding 
clinical decision making.  Further exploration of the factors influencing this variation is 
warranted. 
The majority of respondents would consider injections for HSP, but only 54.4% thought 
it was effective.  The reasons for this remain unclear, but may emphasise difficulties clinicians 
have in relation to clinical reasoning for this intervention.  Clinicians reported they injected for 
HSP very infrequently with 83% having done three or less injections in the last three months.  
This may be related to the main barriers to injecting found in this study.  If clinicians have 
difficulty determining the cause of HSP then there will undoubtedly be uncertainty in the 
management of the pain.  This finding compliments the work of Bakheit et al [28] who in an 
international survey found an infrequency of shoulder injections in practice and postulated that 
this could be due to the complex and multifactorial nature of HSP. 
Interestingly, in this study, pectoralis major was overwhelmingly the muscle most often 
selected to treat HSP.  Yet in the literature, pectoralis major and subscapularis have been 
investigated equivalently.  This disparity between research and clinical practice could be 
speculated to be due to several reasons including the difficulty of injecting subscapularis and 
the potential need for imaging.  However, if a restriction of shoulder external rotation is 
associated with the development of HSP [29] then subscapularis should be given more 
consideration in clinical practice given that it is the main force producer of internal rotation at 
the shoulder [30]. 
The BoNT-A doses that were reported in this study deviated notably from the RCP 
guidelines for spasticity management [23].  Franke et al [31] report that more experienced 
clinicians may be less likely to follow clinical guidelines than their less experienced 
counterparts.  The large number of experienced clinicians in this study could therefore account 
for this deviation.  Interestingly, studies [14,17] have found a positive effect of BoNT-A on 
HSP when they used approximately double the dose of that suggested in guidelines, suggesting 
that the larger doses suggested in this study may indeed be warranted to achieve an analgesic 
effect in HSP. 
This gap between evidence and clinical practice is a common finding in many areas and 
is well documented in the literature [32,33]. There are many barriers to changing practice in 
response to guidelines reported in the literature [34].  Whilst an understanding of the specific 
barriers to evidence-based practice is thought to be a crucial first-step to bridge the gap between 
evidence and practice, it is still not understood what the most effective strategies to achieve 
this change are [35].  To this end, an initial exploration of the specific factors that impact on 
the uptake of clinical guidelines in spasticity management would be useful, particularly on the 
matter of dosing. 
As previously discussed, the literature reports difficulties in determining causation of 
HSP due to the multifactorial nature of the condition [8].  Understanding the factors that would 
help a clinician identify which patients would respond to this intervention is paramount to 
optimise the effectiveness of BoNT-A injections.  Through consensus of opinion, this study 
has identified that clinicians feel limitation of shoulder abduction and external rotation, flexor 
patterning of the upper limb, and pain on passive movement are the symptoms that would lead 
them to decide the HSP was due to spasticity over other causes.  Further studies are required 
to investigate whether these symptoms effectively identify those patients who would most 
benefit from BoNT-A injections for HSP. 
With regards to the timing of intervention, the survey showed that only 11.9% would 
consider injections within the first two weeks, which increased to 40.1% between two and four 
weeks.  This is in comparison to the 83.1% who would consider injections between one to six 
months.  This finding could be due to a concern that using BoNT-A injections early may inhibit 
motor recovery and clinicians may prefer to use a ‘wait and see’ approach at that point.  It 
could also be that, when completing the survey, respondents were mindful of the typical initial 
post-stroke stage of flaccid paralysis which would negate the need for BoNT-A.  However, in 
observational studies, spasticity was present in 21% [36] to 24.5% [37] of patients within the 
first two weeks post-stroke.  Ward [38] comments that early intervention with BoNT-A may 
reduce severity, delay the progression, or even prevent the onset of spasticity after stroke.  
Therefore, if early identification and treatment of HSP associated with spasticity could be 
achieved then outcomes may be improved. 
 
 
Limitations 
Limitations of this study include the inherent biases that can occur with an online survey of 
this nature.  There may have been a degree of self-selection bias as clinicians with a particular 
interest in the topic area may be more likely to opt in to the study, leading to under-coverage 
of the targeted sample [39].  It is also possible that there may have been a degree of social 
desirability bias if subjects reported what they felt was expected practice rather than their actual 
routine practice [40]. 
The response rate was low but this was not unexpected for a survey of this type where 
the subject matter is such a focussed specialism [41].  The use of British Society for 
Rehabilitation Medicine and British Neurotoxin Network as distributors provided anonymity 
and credibility whilst targeting clinicians most likely to be involved in spasticity management.  
Efforts were made to optimise the response rate by developing a short, relevant survey and 
through the use of reminder emails [42].  Nonetheless, certain areas of the UK had only one or 
two respondents.  Without an understanding of the location and number of injectors in the UK 
it is unclear if this is an under-representation of certain areas or due to a reduced response rate 
in general.  In actuality, the overall response rate is likely to be higher than reported as the 
calculation used did not allow for invalid or inactive email addresses or respondents with 
multiple addresses in the database. 
Finally, whilst every effort was made to ensure the clarity and readability of the survey 
through numerous reviews and refinement, there is the possibility that participants may have 
misunderstood the phrasing of questions [42].  In turn this could have led to frustration and 
explain the desire of a number of subjects to leave the survey before completion [43].  
 
 
 
Further Research 
Observational studies would be beneficial to better describe this complex intervention and to 
determine the conditions in which the intervention works most effectively [44].  This would 
identify areas of focus that could then be explored using experimental designs with 
comparative methods.  Factors such as muscle selection, dose, and volume of injectate need to 
be more thoroughly explored to aid clinical reasoning for this intervention.  It would also be 
beneficial to identify which patients are most likely to gain from this treatment to optimise the 
success rate.  In the future, longitudinal studies investigating the timing of the intervention 
post-stroke to assess whether early BoNT-A injections could have a prophylactic effect on HSP 
would be worthwhile. 
  
Conclusion 
Current UK practice of BoNT-A injections for HSP associated with spasticity is highly 
variable.  The causes for this remain unclear.  There are also gaps between contemporary 
practice and the available evidence and guidelines, most notably in relation to muscle selection 
and the doses used.  Further research is required to ascertain the most effective treatment 
approach and for optimal patient selection.  An understanding of the early clinical signs of 
patients at risk of developing HSP associated with spasticity warrants further exploration as 
early intervention may reduce or prevent the complications associated with HSP.   
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Figures & Tables 
 
 
Figure 1.  Respondents % per UK region (n=68) 
 
 
 
 
Table 1. Demographic characteristics (n=68) 
 
  % (n) 
Profession Medical 73.5 (50) 
 Physiotherapy 25.0 (17) 
 Nursing 1.5 (1) 
Number of years 
injecting BoNT-A 0-2 7.4 (5) 
 3-5 20.6 (14) 
 6-10 17.6 (12) 
 Over 10 54.4 (37) 
Frequency of BoNT-A 
injections per month 0-5 14.7 (10) 
 6-10 25.0 (17) 
 11-15 16.2 (11) 
 16-20 10.3 (7) 
 Over 20 33.8 (23) 
 
 
 
 
 
 
Table 2. Barriers to BoNT-A injections for HSP (n=68) 
 
Barriers % (n) 
None – I have no barriers to this 45.6 (31) 
Difficulty determining cause of pain 29.4 (20) 
Difficult to isolate muscles for injection 27.9 (19) 
Lack of evidence 25.0 (17) 
Other treatment options are more effective 16.2 (11) 
Uncertain of muscle anatomy 10.3 (7) 
Unable to access required equipment 5.9 (4) 
Difficulty in obtaining funding for toxin or service 5.9 (4) 
Need for imaging when injecting subscapularis 4.4 (3) 
Delays with referrals 2.9 (2) 
Concerns regarding safety 1.5 (1) 
  
 
 
 
 
Table 3. Respondents use of BoNT-A injections for HSP (n=59) 
 
  % (n) 
Number of injections for HSP 
in last 3 months 0 22.0 (13) 
 1-3 61.0 (36) 
 4-6 8.5 (5) 
 Over 10 8.5 (5) 
Post-stroke stages where 
BoNT-A considered for HSP 0-13 days 11.9 (7) 
 2-4 weeks 40.1 (24) 
 1-3 months 83.1 (49) 
 3-6 months 83.1 (49) 
 6-12 months 66.1 (39) 
 Over 1 year 62.7 (37) 
Signs and symptoms that HSP 
is due to spasticity Limitation of shoulder abduction 71.2 (42) 
 Limitation of shoulder external rotation 69.5 (41) 
 Flexor patterning in the upper limb 61.0 (36) 
 Pain on passive movement 54.2 (32) 
 Malalignment 39.0 (23) 
 Pain on active movement 25.4 (15) 
 Pain on palpation of muscle 22.0 (13) 
 Pain described as dull ache 16.9 (10) 
 Pain described as sharp shooting 11.9 (7) 
 Night pain 10.2 (6) 
 Pain at rest 8.5 (5) 
   
 
 
 
 
Table 4. All muscles reported that respondents would consider for BoNT-A injections (n=59)  
 
Muscle % (n) 
Pectoralis major 83.1 (49) 
Subscapularis 28.9 (17) 
Biceps brachii 16.9 (10) 
Teres major 16.9 (10) 
Latissimus dorsi 16.9 (10) 
Trapezius 13.6 (8) 
Supraspinatus 6.8 (4) 
Infraspinatus 3.4 (2) 
Levator scapulae 3.4 (2) 
Deltoid 3.4 (2) 
Rhomboids 1.7 (1) 
Triceps brachii 1.7 (1) 
Pectoralis minor 1.7 (1) 
Brachialis 1.7 (1) 
Brachioradialis 1.7 (1) 
 Table 5. Doses and volumes of injectate of 5 most common muscles 
 
 Pectoralis 
major 
(n=46) 
Subscapularis 
(n=17) 
Biceps 
brachii 
(n=10) 
Teres 
major 
(n=10) 
Latissimus 
dorsi 
(n=10) 
Dose 
comparison 
(%) 
Under 
recommended 
dose 
47.8 11.8 20.0 0.0 20.0 
Within 
recommended 
dose 
30.4 23.5 70.0 20.0 30.0 
Over 
recommended 
dose 
21.7 64.7 10.0 80.0 50.0 
Volume 
(ml) 
Min. 0.40 0.30 0.30 0.30 0.30 
Max. 4.00 4.00 2.50 2.00 5.00 
Mean (SD) 1.41 
(0.91) 
1.35 (1.01) 1.53 
(0.82) 
0.97 
(0.62) 
2.23 
(1.57) 
 
 
 
 
 
